These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 20108509)

  • 21. The impact of dose of the angiotensin-receptor blocker valsartan on the post-myocardial infarction ventricular remodeling: study protocol for a randomized controlled trial.
    Cho YR; Kim YD; Park TH; Park K; Park JS; Baek H; Choi SY; Kim KS; Hong TJ; Yang TH; Hwang JY; Park JS; Hur SH; Lee SG
    Trials; 2011 Nov; 12():247. PubMed ID: 22108275
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Is triple combination of different neurohormonal modulators recommended for treatment of mild-to-moderate congestive heart failure patients? (Results of SADKO-CHF study). Part 2].
    Skvortsov AA; Mareev VIu; Nasonova SN; Sychev AV; Arbolishvili GN; Baklanova NA; Masenko VP; Belenkov IuN
    Ter Arkh; 2006; 78(9):61-71. PubMed ID: 17076227
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mortality and morbidity remain high despite captopril and/or Valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction: results from the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
    White HD; Aylward PE; Huang Z; Dalby AJ; Weaver WD; Barvik S; Marin-Neto JA; Murin J; Nordlander RO; van Gilst WH; Zannad F; McMurray JJ; Califf RM; Pfeffer MA;
    Circulation; 2005 Nov; 112(22):3391-9. PubMed ID: 16301343
    [TBL] [Abstract][Full Text] [Related]  

  • 24. AT2 receptor mediates the cardioprotective effects of AT1 receptor antagonist in post-myocardial infarction remodeling.
    Oishi Y; Ozono R; Yoshizumi M; Akishita M; Horiuchi M; Oshima T
    Life Sci; 2006 Dec; 80(1):82-8. PubMed ID: 17023005
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The impact of nitrates and mono-therapy and nitrates combined with angiotensin converting enzyme inhibitors on left ventricular remodeling and exercise capacity in patients after acute myocardial infarction].
    Maciejewicz J; Maziarz A; Celibała R; Wiśniewski M; Wiśniewska M
    Przegl Lek; 2003; 60(2):80-4. PubMed ID: 12939852
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pretreatment with angiotensin receptor blockade prevents left ventricular dysfunction and blunts left ventricular remodeling associated with acute myocardial infarction.
    Thai H; Castellano L; Juneman E; Phan H; Do R; Gaballa MA; Goldman S
    Circulation; 2006 Oct; 114(18):1933-9. PubMed ID: 17060375
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Angiotensin receptor neprilysin inhibitor LCZ696 attenuates cardiac remodeling and dysfunction after myocardial infarction by reducing cardiac fibrosis and hypertrophy.
    von Lueder TG; Wang BH; Kompa AR; Huang L; Webb R; Jordaan P; Atar D; Krum H
    Circ Heart Fail; 2015 Jan; 8(1):71-8. PubMed ID: 25362207
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of valsartan, an angiotensin II receptor blocker, on coronary atherosclerosis in patients with acute myocardial infarction who receive an angiotensin-converting enzyme inhibitor.
    Yano H; Hibi K; Nozawa N; Ozaki H; Kusama I; Ebina T; Kosuge M; Tsukahara K; Okuda J; Morita S; Umemura S; Kimura K
    Circ J; 2012; 76(6):1442-51. PubMed ID: 22473458
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The impact of a dose of the angiotensin receptor blocker valsartan on post-myocardial infarction ventricular remodelling.
    Park K; Kim YD; Kim KS; Lee SH; Park TH; Lee SG; Kim BS; Hur SH; Yang TH; Oh JH; Hong TJ; Park JS; Hwang JY; Jeong B; Bae WH;
    ESC Heart Fail; 2018 Apr; 5(2):354-363. PubMed ID: 29341471
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Changes in left ventricular mass and volumes in patients receiving angiotensin-converting enzyme inhibitor therapy for left ventricular dysfunction after Q-wave myocardial infarction.
    Foster RE; Johnson DB; Barilla F; Blackwell GG; Orr R; Roney M; Stanley AW; Pohost GM; Dell'Italia LJ
    Am Heart J; 1998 Aug; 136(2):269-75. PubMed ID: 9704689
    [TBL] [Abstract][Full Text] [Related]  

  • 31. VALIANT (VALsartan In Acute myocardial iNfarcTion) trial.
    Maggioni AP; Fabbri G
    Expert Opin Pharmacother; 2005 Mar; 6(3):507-12. PubMed ID: 15794740
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Additive amelioration of left ventricular remodeling and molecular alterations by combined aldosterone and angiotensin receptor blockade after myocardial infarction.
    Fraccarollo D; Galuppo P; Schmidt I; Ertl G; Bauersachs J
    Cardiovasc Res; 2005 Jul; 67(1):97-105. PubMed ID: 15949473
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of combination of ACE inhibitor and angiotensin receptor blocker on cardiac remodeling, cardiac function, and survival in rat heart failure.
    Kim S; Yoshiyama M; Izumi Y; Kawano H; Kimoto M; Zhan Y; Iwao H
    Circulation; 2001 Jan; 103(1):148-54. PubMed ID: 11136700
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Left ventricular assessment in myocardial infarction: the VALIANT registry.
    Hernandez AF; Velazquez EJ; Solomon SD; Kilaru R; Diaz R; O'Connor CM; Ertl G; Maggioni AP; Rouleau JL; van Gilst W; Pfeffer MA; Califf RM;
    Arch Intern Med; 2005 Oct; 165(18):2162-9. PubMed ID: 16217008
    [TBL] [Abstract][Full Text] [Related]  

  • 35. JIKEI HEART Study--a morbi-mortality and remodeling study with valsartan in Japanese patients with hypertension and cardiovascular disease.
    Mochizuki S; Shimizu M; Taniguchi I; Kanae K; Yoshida S; Tajima N; Dahlöf B;
    Cardiovasc Drugs Ther; 2004 Jul; 18(4):305-9. PubMed ID: 15367828
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The stress hyperglycaemia ratio is associated with left ventricular remodelling after first acute ST-segment elevation myocardial infarction.
    Meng S; Zhu Y; Liu K; Jia R; Nan J; Chen M; Lei X; Zou K; Jin Z
    BMC Cardiovasc Disord; 2021 Feb; 21(1):72. PubMed ID: 33541271
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rationale and design of a multi-center, prospective randomized controlled trial on the effects of sacubitril-valsartan versus enalapril on left ventricular remodeling in ST-elevation myocardial infarction: The PERI-STEMI study.
    Diao K; Wang D; Chen Z; Wu X; Ma M; Zhu Y; Zhang L; Wang H; Wang M; He S; Li C; Deng Q; Yan T; Wu T; Tang L; Huang B; Sun J; He Y
    Clin Cardiol; 2021 Dec; 44(12):1709-1717. PubMed ID: 34668596
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Do the remodeling effects of sacubitril/valsartan treatment depend upon heart failure duration?
    Villani A; Ravaro S; Cerea P; Caravita S; Ciambellotti F; Branzi G; Munforti C; Parati G; Malfatto G
    J Cardiovasc Med (Hagerstown); 2020 Sep; 21(9):682-687. PubMed ID: 32744827
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of valsartan on left ventricular myocardial functions in hypertensive patients with left ventricular hypertrophy.
    Kucukler N; Kurt IH; Topaloglu C; Gurbuz S; Yalcin F
    J Cardiovasc Med (Hagerstown); 2012 Mar; 13(3):181-6. PubMed ID: 22306782
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intramyocardial dissecting hematoma in anterior wall ST elevation myocardial infarction: impact on left ventricular remodeling and prognosis.
    Spinelli L; Stabile E; Giugliano G; Morisco C; Giudice CA; Imbriaco M; Santoro M; Esposito G; Trimarco B
    Int J Cardiovasc Imaging; 2018 Feb; 34(2):201-210. PubMed ID: 28766162
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.